AZ and Chi-Med scores early data for savolitinib combos in lung cancer, WuXi AppTec buys a U.S. CRO, FDA clears Sun's Dadra plant.

Merck & Co. plans to jettison three U.S. sales teams and 1,800 associated staffers while creating a new, 960-employee chronic care force.

Reckitt Benckiser, rumored to be eyeing a bid for Pfizer’s OTC unit, is making some big changes to its own consumer health operations.

Roche managed 6% growth in the third quarter, but performance from key cancer meds highlighted biosimilar erosion ahead.

With an FDA committee nod, Novo Nordisk is one step closer to rolling out its key diabetes drug semaglutide—and launch preps are underway.

Investors and analysts just can’t get enough of pharma breakups—and Allergan may be the next subject of their enthusiasm.

Kite's new CAR-T approval vaults it and new parent Gilead into a market first launched by Novartis—and into the debate over high drug prices.

Obesity drugmaker Orexigen may be game for a sale. The question is, is anyone game for a buy?

A new lawsuit alleges that several drugmakers paid bribes in Iraq that helped fuel terrorism.

Ex-Lilly exec Alex Azar may nab the top job at HHS, where he could help pharma navigate some turbulent political waters.